GlassScriptPhysician profile
Charles S Bluhm
NPI 1306822705
$7,480.72
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,493 · 2020: $925 · 2021: $1,889 · 2022: $2,161 · 2023: $12.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,012.98 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,454.88 | 2019-2022 | |
| Pfizer INC. | $1,154.41 | 2019-2022 | |
| Janssen Biotech, INC. | $685.56 | 2019-2022 | |
| Gilead Sciences, INC. | $492.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $339.96 | 2019-2022 | |
| Redhill Biopharma INC. | $204.73 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $194.58 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $149.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $110.46 | 2022 | |
| Nestle Healthcare Nutrition INC. | $100.19 | 2020-2023 | |
| Celgene Corporation | $89.07 | 2021-2022 | |
| Qol Medical, LLC | $86.92 | 2021-2022 | |
| Evoke Pharma, INC. | $67.03 | 2021-2022 | |
| Amgen INC. | $56.00 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.67 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $42.20 | 2019-2020 | |
| Ucb, INC. | $40.41 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $38.79 | 2022 | |
| Boston Scientific Corporation | $24.14 | 2019 | |
| Ardelyx, INC. | $18.27 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.73 | 2022 | |
| Allergan, INC. | $17.60 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.09 | 2021 | |
| Medtronic, INC. | $13.68 | 2021 | |
| Daiichi Sankyo INC. | $11.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bluhm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.